MRFAP1L1

Across TCGA pan-cancer cohorts, MRFAP1L1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of MRFAP1L1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MRFAP1L1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MRFAP1L1 is over-expressed in tumor, although a few such as UCEC and KICH show the opposite, repressed pattern.

LIHC, UCEC, and KICH are the cancer types where MRFAP1L1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MRFAP1L1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.850	<.001	8	view →
UCEC	All	All	−0.553	<.001	8	view →
KICH	All	All	−0.661	<.001	7	view →
BRCA	All	All	+0.224	.001	6	view →
CHOL	All	All	+1.412	<.001	5	view →
THCA	Male	IV	−0.739	.007	4	view →
LUSC	Male	III,IV	−0.484	.025	2	view →
KIRP	All	All	−0.226	.022	2	view →
LUAD	Female	II,III,IV	−0.218	.024	2	view →
STAD	All	II,III,IV	+0.432	.040	1	view →
HNSC	All	III,IV	+0.308	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

MRFAP1L1–LIHC

Open the LIHC breakdown →